Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) – Equities research analysts at HC Wainwright cut their Q1 2027 earnings estimates for shares of Ionis Pharmaceuticals in a research report issued to clients and investors on Friday, July 10th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($0.71) for the quarter, down from their prior forecast of ($0.70). HC Wainwright has a “Buy” rating and a $125.00 price objective on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.73) per share. HC Wainwright also issued estimates for Ionis Pharmaceuticals’ Q2 2027 earnings at ($0.65) EPS and FY2027 earnings at ($1.11) EPS.
Several other equities analysts have also commented on the company. Needham & Company LLC cut their price target on Ionis Pharmaceuticals from $105.00 to $86.00 and set a “buy” rating on the stock in a research note on Thursday, July 9th. TD Cowen reissued a “buy” rating and set a $108.00 target price on shares of Ionis Pharmaceuticals in a research report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, April 21st. Bank of America boosted their price objective on shares of Ionis Pharmaceuticals from $100.00 to $111.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. Finally, Royal Bank Of Canada dropped their target price on Ionis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating on the stock in a research report on Monday. Eighteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Ionis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $96.05.
Ionis Pharmaceuticals Stock Performance
Shares of NASDAQ:IONS opened at $56.75 on Tuesday. The company has a debt-to-equity ratio of 2.75, a quick ratio of 4.09 and a current ratio of 4.10. The firm has a market cap of $9.38 billion, a PE ratio of -27.42 and a beta of 0.36. The firm’s 50 day simple moving average is $75.42 and its 200-day simple moving average is $77.08. Ionis Pharmaceuticals has a one year low of $40.03 and a one year high of $86.74.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.29. The company had revenue of $246.09 million during the quarter, compared to the consensus estimate of $195.56 million. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.Ionis Pharmaceuticals’s revenue was up 86.4% on a year-over-year basis. During the same period last year, the company earned ($0.93) earnings per share.
Insider Buying and Selling at Ionis Pharmaceuticals
In other news, Director Allene M. Diaz sold 10,111 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $85.42, for a total value of $863,681.62. Following the completion of the sale, the director directly owned 3,811 shares in the company, valued at $325,535.62. The trade was a 72.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Holly B. Kordasiewicz sold 362 shares of the business’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $84.30, for a total transaction of $30,516.60. Following the completion of the sale, the executive vice president directly owned 22,096 shares of the company’s stock, valued at approximately $1,862,692.80. The trade was a 1.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 244,038 shares of company stock worth $19,139,399. Corporate insiders own 1.81% of the company’s stock.
Institutional Investors Weigh In On Ionis Pharmaceuticals
Institutional investors have recently bought and sold shares of the company. Jain Global LLC boosted its stake in shares of Ionis Pharmaceuticals by 3,037.4% in the third quarter. Jain Global LLC now owns 225,739 shares of the company’s stock worth $14,768,000 after acquiring an additional 218,544 shares during the last quarter. DAVENPORT & Co LLC lifted its holdings in Ionis Pharmaceuticals by 248.3% in the 4th quarter. DAVENPORT & Co LLC now owns 217,897 shares of the company’s stock valued at $17,238,000 after purchasing an additional 155,334 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Ionis Pharmaceuticals by 548.7% during the fourth quarter. SG Americas Securities LLC now owns 33,409 shares of the company’s stock worth $2,643,000 after buying an additional 28,259 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Ionis Pharmaceuticals by 51.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 42,394 shares of the company’s stock valued at $3,354,000 after buying an additional 14,455 shares during the last quarter. Finally, BlueCrest Capital Management Ltd acquired a new stake in shares of Ionis Pharmaceuticals in the third quarter valued at about $1,529,000. 93.86% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Ionis Pharmaceuticals
Here are the key news stories impacting Ionis Pharmaceuticals this week:
- Positive Sentiment: Ionis started dosing the first participant in its Phase 1/2 ASCEND study of ION337 for Dravet syndrome, which adds another development-stage program to its pipeline and could support long-term optionality. Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
- Neutral Sentiment: Royal Bank of Canada lowered its price target on Ionis Pharmaceuticals to $85 from $100, but kept an “outperform” rating, signaling continued optimism while acknowledging higher near-term risk. RBC lowers Ionis price target
- Neutral Sentiment: Analysts remained split on Ionis, with some commentary highlighting mixed sentiment across healthcare names rather than a clear fundamental change. Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS) and Guardant Health (GH)
- Neutral Sentiment: An investment-law firm announced an investigation into Ionis Pharmaceuticals, which adds headline risk and could keep sentiment cautious until more details emerge. IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)
- Negative Sentiment: Ionis was hit hard after Wainua missed its Phase 3 endpoint, a setback that hurt confidence in the company’s pipeline and appears to be the biggest driver behind the stock’s decline today. The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions (IONS)
- Negative Sentiment: A director sold about $863,682 of stock, which can weigh on investor confidence when combined with the company’s recent clinical setback. Ionis Pharmaceuticals (NASDAQ:IONS) Director Sells $863,681.62 in Stock
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.
Since its founding in 1989 by Dr.
Read More
- Five stocks we like better than Ionis Pharmaceuticals
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
